Replimune Group (NASDAQ:REPL) Shares Down 5.2% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price traded down 5.2% during mid-day trading on Monday . The stock traded as low as $8.70 and last traded at $8.98. 921,331 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 4,867,033 shares. The stock had previously closed at $9.47.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Wedbush raised their target price on Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a report on Monday, June 1st. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a report on Friday, May 29th. Finally, Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. Seven equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $4.88.

Replimune Group Stock Up 3.0%

The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The stock has a fifty day moving average price of $5.18 and a two-hundred day moving average price of $7.27. The company has a market cap of $762.95 million, a P/E ratio of -2.69 and a beta of 0.91.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently modified their holdings of the business. RTW Investments LP increased its position in shares of Replimune Group by 11.6% during the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after acquiring an additional 744,620 shares during the last quarter. Fcpm Iii Services B.V. increased its position in shares of Replimune Group by 6.4% during the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after acquiring an additional 248,672 shares during the last quarter. State Street Corp increased its position in shares of Replimune Group by 26.3% during the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock valued at $35,897,000 after acquiring an additional 768,982 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Replimune Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after acquiring an additional 9,707 shares during the last quarter. Finally, Braidwell LP increased its position in shares of Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after acquiring an additional 2,327,205 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.